CBO
5 Prime Sciences
Montreal, Canada
Biotech Business Leader. Turning causal human biology into strategic partnerships that stop drug failure and accelerate clinical success.
As CBO at 5Prime Sciences, I bridge the gap between deep science and corporate strategy. Drawing on my foundation in chemical engineering and a PhD in bioinformatics, I have spent the last five years helping scale 5Prime Sciences into a global leader in genetic target validation.
Driven by our mission to stop massive capital waste and late-stage clinical failures, we build collaborations with partners who want to build stronger drug programs using human genetics and multi-omics evidence.
Expertise
Does this target truly drive disease in humans?
Association is not causation. The majority of late-stage failures trace back to a target that appeared relevant in preclinical data but never causally drove disease in humans. This is the question human genetics was designed to answer.
Expertise
Will modulating this target change patient outcomes?
A target can cause a disease without having any effect on how it progresses once established. The distinction determines whether an asset belongs in prevention, treatment, or both — and what a Phase II trial actually needs to show.
Expertise
What are the safety risks of modulating this target in humans?
Animal models miss a significant proportion of adverse events that emerge in human trials. Genetic variants that naturally alter target activity offer a different read — one that reflects what target perturbation does across a human population.
Expertise
Are we selecting the right patients — and are there others we have not considered?
The same mechanism can produce a clear signal in one patient population and a null result in another. Genetic stratification identifies where the biology is strongest — and whether the same mechanism extends to populations not yet in scope.